Moderna Inc. (NASDAQ: MRNA) is a healthcare company, listed on the NASDAQ. Alpha Stocks Insight tracks MRNA across all major catalysts: quarterly earnings reports, analyst upgrades and downgrades, mergers and acquisitions, regulatory decisions, and significant price moves driven by sector or macro developments. This page centralises 4 articles published since May 1, 2026, providing investors with timely, data-driven analysis of Moderna Inc.'s financial performance and competitive position. New coverage is added each trading day.
Price
$54.07
Today
-5.17%
Mkt Cap
$21.5B
52W High
$85.60
52W Low
$22.28
Data via Finnhub · refreshes hourly · not financial advice
Moderna added Michael McDonnell, former Biogen CFO with 35+ years of financial leadership, to its board. Shares fell -10.83% Friday while the S&P 500 gained 0.43%.
FDA releases positive briefing documents ahead of a June 18 VRBPAC meeting on Moderna's mFlusiva, as the company also plans three vaccine launches over two years.
MRNA stock falls 1.24% as Q1 results show massive revenue decline and negative margins across the board.
MRNA edged up 0.48% after beating Q1 revenue expectations as international sales and renewed COVID vaccine demand offset domestic weakness.
Important Legal Disclaimer
This is for informational purposes only and is not financial, investment, or tax advice. Past performance is no guarantee of future results. We are not licensed advisors. For Swiss residents: This does not constitute a public offer under FINSA. For EU residents: Not MiFID II compliant advice. For US residents: Not SEC-registered advice. Always consult a qualified professional. Investing involves risk of loss.
Affiliate disclosure: This site may contain affiliate links to brokerage platforms. If you open an account through one of our links, we may earn a commission at no additional cost to you. Affiliate relationships do not influence our editorial content or stock coverage decisions.
Important Legal Disclaimer: This is for informational purposes only and is not financial, investment, or tax advice. Past performance is no guarantee of future results. We are not licensed advisors. For Swiss residents: This does not constitute a public offer under FINSA. For EU residents: Not MiFID II compliant advice. For US residents: Not SEC-registered advice. Always consult a qualified professional. Investing involves risk of loss.